Literature DB >> 8022835

Induction of anergy or active suppression following oral tolerance is determined by antigen dosage.

A Friedman1, H L Weiner.   

Abstract

Oral tolerance was generated to hen egg white lysozyme in the mouse or to guinea pig myelin basic protein in the rat by a low-dose (1 mg) or a high-dose (5-20 mg) feeding regimen. High doses of antigen induced tolerance characterized by anergy with little or no active suppression and increased secretion of interleukin 4 (IL-4). Anergy was shown by an increase in frequency of IL-2-secreting cells following culture in recombinant IL-2. Low doses of antigen induced tolerance characterized by antigen-driven active suppression with increased secretion of transforming growth factor beta (TGF-beta) and IL-4 and minimal anergy. Without further immunization, spleen cells from animals orally tolerized by both regimens secreted increased levels of IL-4 and TGF-beta in an antigen-specific manner. Animals fed high doses secreted more IL-4 and less TGF-beta, whereas those fed low doses secreted more TGF-beta and less IL-4. These results demonstrate that the two feeding regimens induced cell populations that differed in their cytokine secretion profile and their capacity to actively suppress in vitro and to induce anergy. Our results provide a basis for distinguishing different forms of antigen-driven peripheral tolerance and have important implications for orally induced antigen-specific modulation of human autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8022835      PMCID: PMC44268          DOI: 10.1073/pnas.91.14.6688

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Modification of the immune response by oral tolerance: antigen requirements and interaction with immunogenic stimuli.

Authors:  D Melamed; A Friedman
Journal:  Cell Immunol       Date:  1993-02       Impact factor: 4.868

2.  Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization.

Authors:  A Miller; Z J Zhang; R A Sobel; A al-Sabbagh; H L Weiner
Journal:  J Neuroimmunol       Date:  1993-07       Impact factor: 3.478

3.  Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

Authors:  H L Weiner; G A Mackin; M Matsui; E J Orav; S J Khoury; D M Dawson; D A Hafler
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

4.  Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols.

Authors:  D S Gregerson; W F Obritsch; L A Donoso
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

5.  Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.

Authors:  A Miller; A al-Sabbagh; L M Santos; M P Das; H L Weiner
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

6.  Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin.

Authors:  D Melamed; A Friedman
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

Review 7.  Islet cell antigens in insulin-dependent diabetes: Pandora's box revisited.

Authors:  L C Harrison
Journal:  Immunol Today       Date:  1992-09

8.  Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus.

Authors:  J D Peterson; W J Karpus; R J Clatch; S D Miller
Journal:  Eur J Immunol       Date:  1993-01       Impact factor: 5.532

9.  Effects of oral administration of type II collagen on rheumatoid arthritis.

Authors:  D E Trentham; R A Dynesius-Trentham; E J Orav; D Combitchi; C Lorenzo; K L Sewell; D A Hafler; H L Weiner
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

10.  Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination.

Authors:  A H Cross; V K Tuohy; C S Raine
Journal:  Cell Immunol       Date:  1993-02       Impact factor: 4.868

View more
  113 in total

Review 1.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Active suppression in orally tolerized rats coincides with in situ transforming growth factor-beta (TGF-beta) expression in the draining lymph nodes.

Authors:  B S Lundin; M R Karlsson; L A Svensson; L A Hanson; U I Dahlgren; E Telemo
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

3.  Oral tolerance, an active immunologic process mediated by multiple mechanisms.

Authors:  H L Weiner
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

4.  Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta and down-regulation of proinflammatory mediators.

Authors:  J Youn; S-H Hwang; Z-Y Ryoo; M A Lynes; D-J Paik; H-S Chung; H-Y Kim
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

5.  Effect of in vivo administration of anti-CTLA-4 monoclonal antibody and IL-12 on the induction of low-dose oral tolerance.

Authors:  K S Barone; B Herms; L Karlosky; S Murray; J Qualls
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

6.  What dogs may teach humans about the vertical transmission of allergy predisposition.

Authors:  Barbara Zemann; Antal Rot
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

7.  Multiple fragments of human TG are capable of inducing oral tolerance to whole human TG.

Authors:  C A Gardine; F Gentile; C Pellegrini; F Giallauria; G Torelli; T Kouki; L DeGroot
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 8.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

9.  Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit.

Authors:  J B Sun; C Rask; T Olsson; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

10.  Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice.

Authors:  T Bárdos; M Czipri; C Vermes; J Zhang; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.